rs12139150 - RNU6-481P - FCGR2A
Magnitude 2.2 · 1 study on file
Reported associations
-
Genome-wide association analyses define pathogenic signaling pathways and prioritize drug targets for IgA nephropathy - Unknown journal (n.d.) · Unknown authors · PubMed 37337107
ABSTRACT: IgA nephropathy (IgAN) is a progressive form of kidney disease defined by glomerular deposition of IgA. Here we performed a genome-wide association study of 10,146 kidney-biopsy-diagnosed IgAN cases and 28,751 controls across 17 international cohorts. We defined 30 genome-wide significant risk loci explaining 11% of disease risk. A total of 16 loci were new, including TNFSF4/TNFSF18, REL, CD28, PF4V1, LY86, LYN, ANXA3, TNFSF8/TNFSF15, REEP3, ZMIZ1, OVOL1/RELA, ETS1, IGH, IRF8, TNFRSF13B and FCAR. The risk loci were enriched in gene orthologs causing abnormal IgA levels when genetically manipulated in mice. We also observed a positive genetic correlation between IgAN and serum IgA levels. High polygenic score for IgAN was associated with earlier onset of kidney failure. In a compr
Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.
Lifestyle context
Concrete actions anchored to the cited research. We do not prescribe, we describe.
Discuss with your doctor
-
genetic risk for IgA nephropathy Moderate
Genetic carrier status warrants physician awareness for appropriate screening and nephrology referral consideration
Share rs12139150-G carrier status with physician
Screening
-
kidney disease and IgA nephropathy screening Moderate
Carriers of rs12139150-G have 1.093x increased risk for IgA nephropathy
Discuss screening schedule and intervals with kidney specialist or primary care physician